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E-mail address: hung1228@ms10.hinet.net (W.-C.Prospero-related homeobox 1 (PROX1) is important for liver development and down-regulation of
this transcription factor in hepatocellular carcinoma (HCC) is associated with poor prognosis. We
ﬁnd that PROX1 expression is inversely correlated with the expression of epithelial–mesenchymal
regulator TWIST1 in HCC cell lines and tumor tissues. We demonstrate that PROX1 directly binds
to proximal promoter of TWIST1 gene to repress its transcription and inhibits its downstream target
gene AKT2 expression which leads to reduction of cell migration and invasion. Moreover, PROX1
attenuates lung metastasis of HCC in vivo. These results support an anti-metastatic role of PROX1
via inhibiting TWIST1.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC), one of the most prevalent can-
cers in the world, consists of 85% of primary liver cancers [1]. Pa-
tients with HCC have poor prognosis due to the high potential of
recurrence and intra-hepatic metastasis [2]. Recent evidences sug-
gest that epithelial to mesenchymal transition (EMT) may play an
essential role in tumor metastasis. Several transcription factors
such as SNAIL, TWIST1 and ZEB1/2 are key regulators of EMT and
their expressions cause down-regulation of E-cadherin and other
cell–cell junction proteins which leads to the gaining of mesem-
chymal traits and cancer cells become more aggressive and inva-
sive [3,4]. Among these regulators, TWIST1 has been found to be
over-expressed in HCC and is strongly associated with metastasis
[5]. Subsequent studies demonstrated that TWIST1 increased
migration, invasion and angiogenesis in this cancer [6,7]. More re-
cently, Yang et al. provided evidence that TWIST1 may collaborate
with SNAIL to promote HCC metastasis [8].
Prospero-related homeobox 1 (PROX1) was originally cloned as
a homeobox gene which homologous to the Drosophila prospero
gene and its expression was detected in lens, heart, liver, kidney,
skeletal muscle, pancreas, and central nervous system [9,10]. Addi-
tionally, PROX1 has been shown to be critical for the developmentchemical Societies. Published by E
of Cancer Research, National
inan 704, Taiwan, ROC. Fax:
Hung).of liver and is thoroughly expressed from embryonic hepatoblasts
to adult hepatocytes [11,12]. Recently, an elegant study reveals the
potential role of PROX1 in hepatocytes by demonstrating that
PROX1 interacts with estrogen receptor a and proliferator-acti-
vated receptor c co-activator-1a to regulate the respiratory capac-
ity and energy metabolism [13]. These results suggest that PROX1
is a physiological regulator of liver metabolic function. However,
reduction of PROX1 was found in HCC and cholangiocellular carci-
noma (CCC) and was associated with poor prognosis for HCC impli-
cating a tumor suppressor role [14,15].
Whether PROX1 is involved in the process of HCC development
is unclear. In this study, the effect of PROX1 on invasion of HCC
cells was studied. We found that PROX1 directly repressed the
transcription of an important EMT regulator TWIST1 which led to
down-regulation of expression of AKT2, a TWIST1 target gene. Inhi-
bition of TWIST1 and AKT2 protein reduced migration and invasion
of HCC cells. In addition, we demonstrated that PROX1 suppressed
lung metastasis of HCC in vivo. Our results provide a molecular ba-
sis for the anti-invasive and anti-metastatic action of PROX1.
2. Materials and methods
2.1. Cell culture and experimental reagents
Four HCC cell lines HepG2, Hep3B, Mahlavu and SK-HEP-1 were
provided by Dr. Ming-Hong Tai (National Sun Yat-sen University,
Kaohsiung, Taiwan). Flag-tagged PROX1 vector was a gift of You
Hua Xie (Shanghai Institute for Biological Sciences, Shanghai,lsevier B.V. All rights reserved.
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by Dr. Min-Liang Kuo (National Taiwan University, Taipei, Taiwan).
MYC-tagged TWIST1, HA-tagged AKT2, full-length TWIST1 pro-
moter and its subsequent truncation mutants were provided by
Dr. Lu-Hai Wang (National Health Research Institutes, Miaoli,
Taiwan). Anti-PROX1 antibody (07-537) was purchased from
UpState (Charlottesville, VI) and anti-Actin antibody (MAB1501)
was obtained from Millipore (Billerica, MA). Anti-TWIST1 (H81)
and anti-MYC (9E11) were purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Anti-AKT2 (4057) antibody was obtained
from New England Biolabs (Ipswich, MA). shRNAs were purchased
from the National RNAi Core Facility of Academic Sinica (Taipei).
2.2. RNA isolation, reverse transcription-polymerase chain reaction
and Western blotting
These assays were done as described previously [16]. The pri-
mer sequences used are shown in Supplementary Fig. 1.
2.3. Construction of mutant TWIST1 promoter-reporter plasmids
Full-length human TWIST1 promoter containing 969 to +1 re-
gion and its deletion constructs were generated as described [17].
Mutations were introduced into the putative PROX1 binding sites
of TWIST1 promoter by the QuikChange Site-directed mutagenesis
kit according to the procedures of manufacturer (Stratagene). The
primer sequences used for mutagenesis are shown in Supplemen-
tary Fig. 2.
2.4. Promoter activity assay
Promoter activity of TWIST1 gene was analyzed as described
previously [17]. In brief, cells were plated onto 12-well plates atFig. 1. PROX1 negatively regulates TWIST1 expression. (A) Expression of PROX1, TWIST1,
HEP-1; MA: Mahlavu). (B) SK-HEP-1 and Mahlavu cells were transfected with pcDNA, PRO
Expressions of PROX1 and TWIST1 mRNA and protein were determined. (C) HepG2 and H
48 h. PROX1 and TWIST1 mRNA and protein level were studied. (D) Correlation between
GSE9843. Correlation coefﬁcient and p-value were shown.the density of 100,000 cells/well and grown overnight. The full-
length, deletion or mutant promoter-luciferase constructs were
transfected into cells with pcDNA (control), Flag-tagged PROX1
vector, luciferase (Luc) or PROX1 shRNA. After transfection, cells
were incubated in medium containing 10% FCS for 48 h and pro-
moter activity was determined by using the Fireﬂy luciferase as-
say system (Promega Corp.) and normalized for the
concentration of cellular proteins. Results were evaluated by
the Student’s t-test and p-value <0.05 was considered
signiﬁcant.
2.5. Chromatin immunoprecipitation assay
pcDNA or Flag-tagged PROX1-transfected cells were ﬁxed with
1% formaldehyde at 37 C for 10 min. Cells were harvested and
chromatin immunoprecipitation assay was done as described pre-
viously [18]. Anti-Flag or mouse IgG (as a negative control) were
used for precipitating the protein/DNA complex. DNA fragments
were recovered and subjected to PCR ampliﬁcation by using the
primers speciﬁc for the detection of 192 to 92 bp regions that
contained the PROX1 binding site (117/111) in human TWIST1
gene promoter. The sequences for the primers are forward: 50-
AATGGTTTGGGAGGACGAAT-30, reverse: 50-ACGTGAGGAGGAGG-
GACTTT-30. DNA fragments were also quantiﬁed by using the
real-time PCR detection system (Bio-Rad).
2.6. In vitro migration and invasion and experimental metastasis assay
In vitro migration and invasion assay and tail vein injec-
tion experimental metastasis experiments were performed as
previously described [19,20]. Animal studies were carried out
in nude mice and were approved by the Animal Care and
Ethics Committee of the National Sun Yat-Sen University. MaleE-cadherin and Vimentin in different HCC cell lines (3B: Hep3B; G2: HepG2; SK: SK-
X1 or PROX1 NLS mutant which lacks nuclear localization signal expression vector.
ep3B cells were transfected with luciferase (Luc, as a control) or PROX1 shRNA for
PROX1 and TWIST1 were obtained from two independent datasets GSE14520 and
Fig. 2. PROX1 binds to TWIST1 promoter. (A) Diagram showed the potential PROX1 binding sites in human TWIST1 promoter and the deletion mutants used in this study. (B)
Full-length and deletion mutants of human TWIST1 promoter were co-transfected with pcDNA (Con) or PROX1 expression vector into SK-HEP-1 cells. After 48 h, cells were
harvested for determination of luciferase activity and the promoter activity of cells co-transfected with pcDNA was deﬁned as 100% ⁄p < 0.05 when compared to the control
group. (C) The promoter-luciferase construct containing the 451/+1 TWIST1 promoter region and mutants containing different mutated PROX1 sites were co-transfected
with pcDNA or PROX1 expression vector into SK-HEP-1 cells. After 48 h, cells were harvested for determination of luciferase activity and the promoter activity of cells co-
transfected with pcDNA and wild type 451/+1 twist promoter was deﬁned as 100% ⁄p < 0.05. (D) Chromatin immunoprecipitation (ChIP) assay indicated the binding of
PROX1 to TWIST1 promoter was increased in PROX1-overexpreesing cells (top panel). Quantitative PCR was shown at bottom panel ⁄p < 0.05.
Fig. 3. Endogenous PROX1 binds TWIST1 promoter and controls its transcription. (A) The promoter-luciferase construct containing the 451/+1 TWIST1 promoter region (WT)
and mutants containing different mutated PROX1 sites was transfected into HepG2 cells that expressed high level of endogenous PROX1 protein and the promoter activity
was determined. (B) ChIP assay was conducted to study the binding of PROX1 to TWIST1 promoter (left panel). Quantitative PCR was shown at right panel ⁄p < 0.05. (C) The
451/+1 TWIST1 promoter-luciferase construct was transfected into HepG2 cells expressing luciferase (Luc) or PROX1 shRNA and the promoter activity was determined.
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Fig. 4. TWIST1 reverses PROX1-inhibited migration and invasion via AKT2. (A) SK-HEP-1 cells were transfected with control (Con), PROX1, AKT1 or AKT2 expression vectors.
Cells were subjected to migration and invasion study by using transwell assays. The number of migratory or invasive cells of the control group was deﬁned as 100% ⁄p < 0.05,
when compared to the control group. (B) AKT2 mRNA and protein expression of these cells were studied. (C) Mahlavu cells were transfected with control (Con), PROX1 or
TWIST1 expression vectors and cells were subjected to migration and invasion study described in (A). (D) AKT2 mRNA and protein expression of Mahlavu cells transfected
with different vectors were investigated.
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from National Laboratory Animal Center of National Science
Council (Taipei, Taiwan). Mice were randomly divided into
two groups (n = 5 for each group). pcDNA or Flag-tagged
PROX1-transfected SK-HEP-1 cells (5  105 cells/mice) were in-
jected via tail vein (day 0). Fifteen days after cell injection,
animals were killed. Lungs of the experimental animals were
stained with a contrast medium (15% India ink in distilled
water) by injecting the medium into the trachea and then
ﬁxed in a ﬁxation solution (100 ml of 70% alcohol, 10 ml of
formaldehyde, and 5 ml of glacial acetic acid). The number
of surface tumors was counted.
2.7. Oncomine data analysis
Oncomine (http://www.oncomine.org) is a cancer microarray
database and integrated data-mining platform. Two representa-
tive and independent HCC microarray data sets GSE14520 (sam-
ple size = 130) and GSE9843 (sample size = 91) were used to
analyze the correlation between PROX1 and TWIST1 expression.
The correlation coefﬁcient and p-value were evaluated using
PROX1/207401_at and TWIST1/213943_at, from GSE14520 to
GSE9843, respectively, by statistic program R (a free software
environment for statistical computing and graphics which could
be found at http://www.r-project.org).3. Results
3.1. PROX1 is a negative regulator of TWIST1
Expression of PROX1 was screened in various HCC cell lines. Our
data showed that well-differentiated (epithelial phenotype) HepG2
and Hep3B, but not poorly-differentiated (mesenchymal pheno-
type) SK-HEP-1 and Mahlavu cells expressed PROX1 protein
(Fig. 1A). Comparison of the epithelial–mesenchymal transition
(EMT)-related markers in these cell lines revealed that E-cadherin
was detectable in HepG2 and Hep3B cells while it was absent in
SK-HEP-1 and Mahlavu cells. Conversely, high levels of vimentin
and TWIST1 protein were found in SK-HEP-1 and Mahlavu cells
while these two mesenchymal markers were undetectable or very
low in PROX1-positive HepG2 and Hep3B cells (Fig. 1A). Because
TWIST1 has been demonstrated to play a critical role in the induc-
tion of EMT and invasion of HCCs, we tested whether PROX1 could
affect TWIST1 expression. Ectopic expression of PROX1 in SK-HEP-1
and Mahlava cells led to down-regulation of TWIST1 mRNA and
protein (Fig. 1B). This effect was not observed in cells expressed
a PROX1 mutant protein which could not enter nucleus due to
the mutation of nuclear localization signal (NLS) at the N-terminal
(9–14 a.a.). On the contrary, knockdown of PROX1 by shRNA in
HepG2 and Hep3B cells caused up-regulation of TWIST1 mRNA
and protein (Fig. 1C). These data suggested that PROX1 functions
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tween PROX1 and TWIST1 expression, we examined microarray
data from patient samples contained within the Oncomine data-
base. Indeed, two independent data sets GSE14520 (sample
size = 130) and GSE9843 (sample size = 91) showed a signiﬁcant
inverse correlation between the mRNA level of these two genes
(Fig. 1D). Both cell-based and tissue microarray data suggested that
PROX1 could negatively regulate TWIST1.
3.2. PROX1 down-regulates TWIST1 via transcriptional repression
Two lines of evidences suggested that TWIST1 may be a direct
transcriptional target of PROX1. Firstly, expression of PROX1 re-
duced TWIST1 mRNA level while knockdown of PROX1 caused
up-regulation of TWIST1 mRNA. Secondly, the NLS mutant PROX1
protein could not repress TWIST1 expression because it could not
enter nucleus and bind DNA. Two previously reported Perspero
binding consensus sequences, C[A/T][C/T]NNC[T/C] and CGTCT[T/
A] [21,22], were used to blast the human TWIST1 gene promoter re-
gion. Our results showed that 9 potential PROX1 binding sequences
were identiﬁed between 969 and +1 region of human TWIST1
promoter (Fig. 2A). Deletion of the TWIST1 promoter region from
969 to 451 bp did not affect the inhibition of promoter activity
by PROX1 suggesting the response elements are located at the
451/+1 region (Fig. 2B). Four potential PROX1 binding sites lo-
cated within this region were mutated and we found that only
mutation of the third site (mut-P3) located at 117/111 bp re-
gion effectively reversed PROX1-induced inhibition (Fig. 2C). ChIP
assay clearly demonstrated that PROX1 bound to TWIST1 promoterFig. 5. AKT2 is critical for TWIST1 to reverse PROX1-inhibited migration and invasion. (A
Expression of these proteins was investigated by Western blotting. (B) These cells were a
cells of the control group (Luc) was deﬁned as 100% ⁄p < 0.05 when compared to the
expression of these proteins was investigated by Western blotting. (D) Migration and inwhich contained P3 site and this binding was speciﬁc because
immunoprecipitation with non-immune immunoglobulin did not
yield any signals (Fig. 2D). Quantiﬁcation of the immunoprecipi-
tated DNA fragments by quantitative PCR revealed that a 3.5-fold
increase of PROX1 binding was detected (Fig. 2D). This conclusion
was further conﬁrmed in HepG2 cells which expressed high endog-
enous PROX1. As shown in Fig. 3A, mutation of the P3 site reversed
the inhibition of TWIST1 promoter activity by endogenous Prox1.
ChIP assay veriﬁed the binding of endogenous PROX1 to TWIST1
promoter and knockdown of PROX1 reduced this binding by 70%
(Fig. 3B). Additionally, attenuation of PROX1 promoter binding
was associated with increase of TWIST1 promoter activity
(Fig. 3C). By manipulation of PROX1 level by over-expression or
shRNA silencing, we veriﬁed that PROX1 directly binds to TWIST1
promoter to repress its transcription.
3.3. PROX1 inhibits migration and invasion via inhibiting TWIST1-
induced AKT2
Effect of PROX1 on aggressive behavior of HCC cells was tested.
We found that expression of PROX1 reduced cell migration and
invasion in poorly-differentiated SK-HEP-1 (Fig. 4A). Because Twist
is a transcription factor, it needs to turn on speciﬁc target genes to
promote HCC cell invasion. Lines of evidences suggest that AKT2 is
a potential candidate. Firstly, AKT2, but not AKT1, gene has been
found to be a direct transcriptional target of TWIST1 [23]. Secondly,
AKT2 over-expression was found in HCC and was strongly corre-
lated with poor prognosis [24]. Thirdly, AKT2 is expressed higher
than AKT1 in HCC cell lines [25]. In consistent with our hypothesis,) HepG2 cells were transfected with luciferase (Luc), PROX1, TWIST1 or AKT2 shRNA.
lso subjected to migration and invasion assays. The number of migratory or invasive
control group. (C) Hep3B cells were transfected with various shRNA and protein
vasion of these cells were studied.
T.-M. Chang, W.-C. Hung / FEBS Letters 586 (2012) 3746–3752 3751ectopic expression of AKT2, but not AKT1, fully counteracted the
inhibition of migration and invasion by PROX1 in SK-HEP-1 cells
(Fig. 4A). In addition, enforced expression of PROX1 reduced
AKT2mRNA and protein in SK-HEP-1 cells which could be reversed
by TWIST1 (Fig. 4B). Similar results were obtained in Mahlavu cells
indicating this is not a cell line-speciﬁc effect (Fig. 4C and D). Con-
versely, knockdown of endogenous PROX1 increased TWIST1 and
AKT2 protein level in HepG2 cells (Fig. 5A). In addition, knockdown
of TWIST1 abolished AKT2 protein up-regulation induced by
PROX1 inhibition suggesting TWIST1 acts as an upstream regulator
of AKT2. Migration and invasion of HepG2 cells were increased
after knocking down of PROX1 (Fig. 5B). When TWIST1 or AKT2
was simultaneously inhibited by shRNA, this increase was signiﬁ-
cantly repressed. Similar results were also obtained in Hep3B cells
(Fig. 5C and D). It should be noted that TWIST1 and AKT2 shRNA
did not affect basal migratory and invasive ability of HepG2 and
Hep3B cells because these cells expressed few TWIST1 and AKT2
proteins (Supplementary Fig. 3). After knockdown of PROX1,
TWIST1 and AKT2 levels signiﬁcantly went up and cell migration/
invasion was enhanced. Then, these cells became sensitive to
TWIST1 and AKT2 shRNA indicating the inhibitory effect of these
two shRNAs is speciﬁc. Our data suggested that PROX1 inhibits
migration and invasion of HCC cells via suppressing the TWIST1/
AKT2 axis.
3.4. Inhibition of lung metastasis by Prox1 in vivo
Anti-metastatic effect of PROX1 was also tested in vivo. Control-
and PROX1-expressing SK-HEP-1 cells were injected via tail vein
and lung metastatic nodules were checked at 15 days after injec-
tion. Our data showed that number of metastatic nodules on lung
surfaces was dramatically reduced by 80–85% in PROX1-express-
ing group (Supplementary Fig. 4).4. Discussion
Although PROX1 has been suggested to play a tumor suppres-
sive role in a variety of cancers, including HCC, CCC, hematologic
malignancies, breast cancer, and pancreatic cancer [14,15,26,27],
the detailed anti-cancer mechanism is still obscure. Our study pro-
vides evidence that PROX1 directly inhibits TWIST1 gene expres-
sion which causes AKT2 down-regulation and consequently
prevents metastatic colonization of HCC cells.
TWIST1 is an important oncogene and EMT regulator which
promotes cancer progression via different mechanisms. One of
the ﬁrst TWIST1 transcriptional targets identiﬁed is E-cadherin
[28]. Twist directly binds to E-cadherin promoter to repress its
expression. Down-regulation of E-cadherin subsequently attenu-
ates cell-cell adhesion and enhances cell migration and invasion.
Increase of angiogenesis also is involved in TWIST1-promoted can-
cer progression because TWIST1 enhances production of vascular
endothelial growth factors in breast cancer [29]. Because TWIST1
is up-regulated in many cancers, it seems to be a potential target
for cancer therapy. However, the mechanism of TWIST1 over-
expression in cancer cells is still unclear and it may be cancer
type-dependent. In this study, we demonstrate that TWIST1 is a
transcriptional repression target of PROX1 because PROX1 binds
TWIST1 promoter in vivo (as shown by ChIP assay) and represses
TWIST1 promoter activity via the potential binding site located
at the 117/111 bp of the promoter region. In addition, we iden-
tify a downstream mediator AKT2 which mediates PROX1-induced
metastatic inhibition. Our results provide the ﬁrst molecular basis
to explain the anti-metastatic action of PROX1 in HCC cells.
The regulation of AKT2 by PROX1 is a critical ﬁnding. By using
transgenic models, it is found that different isoforms of AKT playdistinct roles in mammary tumor progression [30,31]. The authors
conclude that AKT1 is important for cancer induction (or initiation)
and AKT2 is primarily involved in metastatic dissemination. Simi-
larly, AKT2 plays a critical role in the establishment of colorectal
cancer metastasis [32]. However, overexpression of AKT1 could
not restore metastatic potential in cells with down-regulated
AKT2 indicating non-redundant roles for individual AKT isoforms
and emphasize the speciﬁc function of AKT2 in metastasis. The un-
ique role of AKT2 is also veriﬁed by this study which demonstrates
that only AKT2 could rescue PROX1-inhibited migration and inva-
sion. Because tail vein injection model mainly assesses the steps of
extravasion, adhesion and colonization, further experiments will
be needed to clarify the detailed mechanism of AKT2-mediated
metastasis of HCC cells.
In summary, we demonstrate that PROX1 is a metastatic repres-
sor in HCC cells and identify TWIST1 as a major target of PROX1 to
attenuate metastatic signaling through AKT2. This ﬁnding provides
new insight for HCC metastasis and may be helpful for the devel-
opment of new strategy for treatment and prevention.
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